Core Viewpoint - The strategic investment actions by Jinbo Biotechnology have attracted significant attention, particularly due to the involvement of Zhong Shanshan, China's richest man, who is investing a total of 34.03 billion yuan through his companies [1][2]. Group 1: Investment Details - Jinbo Biotechnology will issue shares to Yangshengtang Co., Ltd., representing 6.24% of its total shares before the issuance, with a financing amount not exceeding 2 billion yuan [2]. - The share transfer agreement between Jinbo's controlling shareholder Yang Xia and Hangzhou Jiushi involves the transfer of 5,753,267 shares at a price of 243.84 yuan per share, totaling 1.403 billion yuan [2][3]. - After the transfer, Yang Xia will hold 50.73% of Jinbo, while Hangzhou Jiushi and Yangshengtang will hold 4.71% and 5.87%, respectively, making Zhong Shanshan the second-largest shareholder of Jinbo with 10.58% ownership [3]. Group 2: Company Overview - Jinbo Biotechnology focuses on the research, development, production, and sales of high-end implantable medical devices made from recombinant human collagen, primarily used in aesthetic medicine and skin repair [4]. - The company achieved significant revenue growth, with sales increasing from 233 million yuan in 2021 to 1.443 billion yuan in 2024, and net profit rising from 57.39 million yuan to 732 million yuan during the same period, reflecting a year-on-year growth rate of over 79% [4]. Group 3: Market Potential - The collaboration between Jinbo and Yangshengtang is expected to leverage their respective strengths in large-scale industrial production and market channel development, addressing the urgent need for a comprehensive production and sales system [5]. - The market for collagen-based skin care products is projected to surpass that of hyaluronic acid by 2026, with the overall market size for collagen in China expected to reach 173.8 billion yuan by 2027, of which recombinant collagen products will account for 1.083 billion yuan, representing 62.3% of the market [5].

Core Viewpoint - The recent stock issuance by Jinbo Biological, controlled by Zhong Shanshan, aims to raise up to 2 billion RMB to support its growth and development in the collagen market, while also indicating a strategic partnership with Yangshengtang [1][2][7]. Group 1: Company Actions and Financials - Jinbo Biological plans to issue no more than 717,566 shares, representing 6.24% of its total shares before the issuance, to raise funds for a humanized collagen protein database and working capital [1][2]. - The total investment for the projects is 200 million RMB, with 57.5% allocated to the collagen protein project and 42.5% for working capital [2]. - Jinbo Biological's stock price has surged since its listing, with a maximum increase of over 800% from its issue price, reaching a peak of 452.29 RMB [3][9]. Group 2: Market Performance and Growth - Jinbo Biological has shown impressive financial growth, with revenue increasing from 233 million RMB in 2021 to 1.443 billion RMB in 2024, and net profit rising from 57.39 million RMB to 732 million RMB in the same period [9]. - The gross margin improved from 82.29% to 92.02%, and net margin increased from 24.38% to 50.68% [9]. - The Chinese collagen market reached 28.7 billion RMB in 2021, growing at 40.7%, with a significant increase in the penetration of recombinant collagen [9]. Group 3: Strategic Partnerships and Future Outlook - Yangshengtang, controlled by Zhong Shanshan, is entering into a strategic partnership with Jinbo Biological, which is expected to enhance business synergies and accelerate the implementation of their strategic goals [7][8]. - The collaboration aims to leverage technological integration and market channel empowerment, potentially leading to significant advancements in product development [7][8]. - Jinbo Biological's need for strategic investors is highlighted by its relatively small size and the increasing competition in the medical aesthetics industry [10][13].

Core Viewpoint - JINBO Biotech is the only company in China with three Class III certifications for injectable recombinant humanized collagen, leading the development of innovative medical materials and aiming to become a global leader in life materials [1][2]. Group 1: Product Development and Innovation - The company has successfully developed a full range of recombinant type III humanized collagen products, including freeze-dried fibers, solutions, and gels, establishing a comprehensive product system [2][3]. - JINBO Biotech's research has led to the first large-scale production of recombinant type III humanized collagen with a 164.88° triple helix structure, marking a significant breakthrough in the field [2][3]. - The company emphasizes the importance of eliminating immunogenicity and achieving large-scale production of collagen materials to meet safety and efficacy demands in medical applications [2][3]. Group 2: Research and Development Investment - In 2024, JINBO Biotech plans to invest 123 million yuan in R&D, an increase of 18.71% year-on-year, representing 8.52% of its revenue [4]. - The company is focusing on various types of humanized collagen projects, with some products already entering clinical trials [4][5]. Group 3: International Collaboration and Standards - JINBO Biotech collaborates with leading companies like L'Oréal to enhance global recognition of its technologies and promote international market penetration [5]. - The company has taken a leading role in establishing international standards for medical devices made from bioengineered materials, enhancing China's technological influence in this field [5]. Group 4: Technological Advancements and AI Integration - The company has established a FAST database for humanized collagen, significantly improving R&D efficiency through AI technology, reducing the time for data screening from one month to one day [6]. - JINBO Biotech integrates advanced technologies such as AlphaFold for protein structure prediction and has established a smart laboratory to ensure data reliability and enhance R&D capabilities [6].

Core Viewpoint - The article highlights the significance of the New Fortune Gold Medal Secretary selection in the Chinese capital market, emphasizing the role of outstanding secretaries in enhancing corporate governance and investor relations, thus contributing to high-quality market development [1]. Company Overview - Jinbo Biological was established in 2008 and is headquartered in Taiyuan, Shanxi. It is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province. The company focuses on the research and industrialization of recombinant humanized collagen [5]. Key Achievements - Jinbo Biological became the first A-share listed company in China centered on "recombinant humanized collagen" after successfully completing its listing on July 20, 2023, on the Beijing Stock Exchange. This milestone serves as a model for the industrialization of original achievements by small and medium-sized enterprises in China [3]. - The company has received multiple approvals for innovative medical devices, including the first medical device product in China using new biological materials, and has established itself as a leader in the production of implant-grade medical devices globally [6][7]. Technological Breakthroughs - Jinbo Biological has achieved three core technological breakthroughs: 1. Safety breakthrough with a protein amino acid sequence highly consistent with natural collagen, showing strong biocompatibility and no immunogenic issues in over 2 million clinical applications [8]. 2. Effectiveness breakthrough with a clear 164.88° flexible triple helix structure, recognized by the international protein database [8]. 3. Application scenario breakthrough with high cell adhesion surpassing natural collagen, demonstrating excellent tissue repair characteristics across various fields [8]. Innovation Strategy - The company adheres to an "original innovation" strategy, having established six major technology platforms and multiple joint research platforms with prestigious institutions, covering the entire chain from basic research to clinical transformation and industrial implementation [9]. Role of the Secretary - The role of the board secretary is crucial in bridging the company and the capital market, requiring solid financial and legal knowledge, as well as excellent communication and coordination skills. The secretary's responsibilities include ensuring compliance, enhancing communication with regulatory bodies, investors, and media, and fostering a transparent public relations environment [14].